A Phase II Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Tolerability, Safety, Pharmacokinetics and Efficacy of Intravenous INO-1001 in High Risk Subjects Undergoing Cardiopulmonary Bypass for Coronary Revascularization and/or Valve Surgery.
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 162
- 试验地点
- 21
- 主要终点
- Reduction in serious post-operative complications occurring in the first thirty days after surgery.
研究概览
简要总结
The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-[ADP ribose] polymerase) inhibitor, in patients undergoing heart surgery. The study also measures whether INO-1001 reduces the side effects caused by heart-lung bypass machines.
详细描述
Heart-lung bypass during heart surgery sometimes leads to side effects or complications after surgery.
Studies have shown that PARP inhibitors protect cells from damage due to lack of oxygen. Heart-lung bypass during heart surgery can result in cells being deprived of oxygen. INO-1001 may be able to protect these cells and reduce complications following surgery.
A total of 162 patients will be randomly assigned to either INO-1001 or placebo (sugar water). Treatment will begin on the day of heart surgery and continue for 36 hours. A total of 4 doses of INO-1001 will be given. Patients will be followed up until 30 days after surgery.
The following information will be collected: symptoms, vital signs, physical examination, blood and urine tests, electrocardiograms, and other information from medical charts.
The information provided in this listing is disclosed solely to comply with regulatory requirements. The drug INO-1001 has not yet been approved for marketing and is only available to patients who participate in a clinical trial and are chosen for the treatment group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients scheduled to undergo cardiopulmonary bypass for coronary revascularization and/or valve surgery
- •Males and non-pregnant, non-lactating females
排除标准
- •Subjects will be required to undergo a full medical review in order to exclude serious medical or psychological illness prior to inclusion
- •History of a hypersensitivity reaction to more than three drugs or to mannitol
- •Participation in any other investigational study within 30 days of the screening phase
- •Known alcohol or drug abuse within the last year
- •Treatment with certain restricted medications within a specified time prior to participation in the study
结局指标
主要结局
Reduction in serious post-operative complications occurring in the first thirty days after surgery.
次要结局
未报告次要终点